UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 29, 2015
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235 East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
YES X
NO ___
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
YES X
NO ___
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):
Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YES ____
NO X
At May 4, 2015, 6,157,669,933 shares of the issuer s voting common stock were outstanding.
Table of Contents
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Income for the three months ended March 29, 2015 and March 30, 2014
Condensed Consolidated Statements of Comprehensive Income for the three months ended March 29, 2015 and March 30, 2014
Condensed Consolidated Balance Sheets as of March 29, 2015 and December 31, 2014
Condensed Consolidated Statements of Cash Flows for the three months ended March 29, 2015 and March 30, 2014
Notes to Condensed Consolidated Financial Statements
Review Report of Independent Registered Public Accounting Firm
35
Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
36
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
79
Item 4.
Controls and Procedures
79
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
80
Item 1A.
Risk Factors
80
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
81
Item 3.
Defaults Upon Senior Securities
81
Item 4.
Mine Safety Disclosures
81
Item 5.
Other Information
81
Item 6.
Exhibits
82
Signature
83
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
(MILLIONS, EXCEPT PER COMMON SHARE DATA)
March 29,
2015
March 30,
2014
Revenues
10,864
11,353
Costs and expenses:
Cost of sales(a)
1,838
2,045
Selling, informational and administrative expenses(a)
3,104
3,040
Research and development expenses(a)
1,885
1,623
Amortization of intangible assets
940
1,117
Restructuring charges and certain acquisition-related costs
60
58
Other (income)/deductions net
(46
623
Income from continuing operations before provision for taxes on income
3,082
2,847
Provision for taxes on income
706
582
Income from continuing operations
2,376
2,265
Discontinued operations net of tax
73
Net income before allocation to noncontrolling interests
2,381
2,338
Less: Net income attributable to noncontrolling interests
Net income attributable to Pfizer Inc.
2,376
2,329
Earnings per common share basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.38
0.35
Discontinued operations net of tax
0.01
Net income attributable to Pfizer Inc. common shareholders
0.38
0.36
Earnings per common share diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.38
0.35
Discontinued operations net of tax
0.01
Net income attributable to Pfizer Inc. common shareholders
0.38
0.36
Weighted-average shares basic
6,203
6,389
Weighted-average shares diluted
6,292
6,476
Cash dividends paid per common share
0.28
0.26
(a)
Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill:Identifiable Intangible Assets.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months Ended
(MILLIONS OF DOLLARS)
March 29,
2015
March 30,
2014
Net income before allocation to noncontrolling interests
2,381
2,338
Foreign currency translation adjustments
(1,308
(75
Reclassification adjustments(a)
(62
(1,308
(137
Unrealized holding losses on derivative financial instruments, net
(315
(58
Reclassification adjustments for realized losses(b)
234
12
(82
(46
Unrealized holding gains/(losses) on available-for-sale securities, net
(328
108
Reclassification adjustments for realized (gains)/losses(b)
247
(99
(81
Benefit plans: actuarial gains, net
32
Reclassification adjustments related to amortization(c)
136
49
Reclassification adjustments related to settlements, net(c)
40
21
Other
158
(17
365
59
Benefit plans: prior service costs and other, net
(1
Reclassification adjustments related to amortization(c)
(35
(18
Reclassification adjustments related to curtailments, net(c)
(10
(4
Other
(1
(46
(23
Other comprehensive loss, before tax
(1,152
(138
Tax provision/(benefit) on other comprehensive loss(d)
105
(17
Other comprehensive loss before allocation to noncontrolling interests
(1,257
(121
Comprehensive income before allocation to noncontrolling interests
1,124
2,217
Less: Comprehensive income/(loss) attributable to noncontrolling interests
(10
Comprehensive income attributable to Pfizer Inc.
1,134
2,210
(a)
Reclassified into Discontinued operations net of tax in the condensed consolidated statements of income.
(b)
Reclassified into Other (income)/deductions net in the condensed consolidated statements of income.
(c)
Generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, in the condensed consolidated statements of income. For additional information, see Note 10. Pension and Postretirement Benefit Plans.
(d)
See Note 5C. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Loss.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS OF DOLLARS)
March 29,
2015
December 31,
2014
(Unaudited)
Assets
Cash and cash equivalents
3,563
3,343
Short-term investments
24,145
32,779
Trade accounts receivable, less allowance for doubtful accounts: 2015 $444; 2014 $412
8,920
8,669
Inventories
5,786
5,663
Current deferred tax assets and other current tax assets
4,214
4,498
Other current assets
2,815
2,750
Total current assets
49,443
57,702
Long-term investments
18,289
17,518
Property, plant and equipment, less accumulated depreciation
11,527
11,762
Identifiable intangible assets, less accumulated amortization
34,334
35,166
Goodwill
41,854
42,069
Noncurrent deferred tax assets and other noncurrent tax assets
1,477
1,544
Other noncurrent assets
3,716
3,513
Total assets
160,640
169,274
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt
6,555
5,141
Trade accounts payable
2,724
3,210
Dividends payable
1,711
Income taxes payable
944
531
Accrued compensation and related items
1,679
1,841
Other current liabilities
8,320
9,197
Total current liabilities
20,222
21,631
Long-term debt
29,370
31,541
Pension benefit obligations, net
6,571
7,885
Postretirement benefit obligations, net
2,480
2,379
Noncurrent deferred tax liabilities
24,474
24,981
Other taxes payable
4,293
4,353
Other noncurrent liabilities
5,644
4,883
Total liabilities
93,053
97,652
Preferred stock
28
29
Common stock
458
455
Additional paid-in capital
80,004
78,977
Treasury stock
(79,100
(73,021
Retained earnings
74,471
72,176
Accumulated other comprehensive loss
(8,557
(7,316
Total Pfizer Inc. shareholders equity
67,304
71,301
Equity attributable to noncontrolling interests
283
321
Total equity
67,587
71,622
Total liabilities and equity
160,640
169,274
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Three Months Ended
(MILLIONS OF DOLLARS)
March 29,
2015
March 30,
2014
Operating Activities
Net income before allocation to noncontrolling interests
2,381
2,338
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization
1,260
1,456
Asset write-offs and impairments
11
137
Deferred taxes from continuing operations
(41
345
Share-based compensation expense
162
143
Benefit plan contributions in excess of expense
(874
(99
Other adjustments, net
(336
(294
Other changes in assets and liabilities, net of acquisitions and divestitures
(1,879
(1,091
Net cash provided by operating activities
685
2,935
Investing Activities
Purchases of property, plant and equipment
(239
(292
Purchases of short-term investments
(7,546
(8,721
Proceeds from redemptions/sales of short-term investments
10,702
7,569
Net proceeds from redemptions/sales of short-term investments with original maturities of 90 days or less
5,243
1,500
Purchases of long-term investments
(3,150
(1,808
Proceeds from redemptions/sales of long-term investments
1,937
1,454
Acquisitions of businesses, net of cash acquired
(678
Acquisitions of intangible assets
(7
(6
Other investing activities, net
330
206
Net cash provided by/(used in) investing activities
6,592
(98
Financing Activities
Proceeds from short-term borrowings
1,998
Principal payments on short-term borrowings
(3
Net proceeds from short-term borrowings with original maturities of 90 days or less
863
1,031
Principal payments on long-term debt
(3,002
(752
Purchases of common stock
(6,000
(1,197
Cash dividends paid
(1,758
(1,662
Proceeds from exercise of stock options
794
425
Other financing activities, net
122
25
Net cash used in financing activities
(6,982
(2,133
Effect of exchange-rate changes on cash and cash equivalents
(74
(25
Net increase in cash and cash equivalents
220
679
Cash and cash equivalents, beginning
3,343
2,183
Cash and cash equivalents, end
3,563
2,862
Supplemental Cash Flow Information
Cash paid during the period for:
Income taxes
372
536
Interest
332
361
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of Presentation and Significant Accounting Policies
A. Basis of Presentation
We prepared the condensed consolidated financial statements following the requirements of the U.S. Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted.
Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three months ended February 22, 2015 and February 23, 2014.
In the condensed consolidated balance sheet as of December 31, 2014, we performed certain reclassifications to conform to current period presentation, none of which were material to our financial statements.
On February 5, 2015, we announced that we have entered into a definitive merger agreement under which we agreed to acquire Hospira, Inc. (Hospira), the world s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, for $90 per share in cash, for a total enterprise value of approximately $17 billion. We expect to finance the transaction through a combination of existing cash and new debt, with approximately two-thirds of the value financed from cash and one-third from debt. The transaction is subject to customary closing conditions, including regulatory approvals in several jurisdictions and the approval of Hospira's shareholders, and is expected to close in the second half of 2015.
Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our condensed consolidated balance sheets and condensed consolidated statements of income.
The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2014 Annual Report on Form 10-K.
Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.
B. Adoption of New Accounting Standard
We adopted a new accounting and disclosure standard as of January 1, 2015 that limits the presentation of discontinued operations to business circumstances when the disposal of the business operation represents a strategic shift that has had or will have a major effect on our operations and financial results. This new standard is applied prospectively to all disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December
15, 2014, and interim periods within those years. We did not have any disposals within the scope of this new standard and, therefore, there were no impacts to our condensed consolidated financial statements.
C. Fair Value
Our fair value methodologies depend on the following types of inputs:
Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).
Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).
Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).
A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 2. Acquisition, Collaborative Arrangements and Equity-Method Investment
A. Acquisition
Marketed Vaccines Business of Baxter International Inc. (Baxter)
On December 1, 2014 (which falls in the first fiscal quarter of 2015 for our international operations), we completed the acquisition of Baxter's portfolio of marketed vaccines for a final purchase price of $648 million. The portfolio that was acquired consists of NeisVac-C and FSME-IMMUN/TicoVac. NeisVac-C is a vaccine that helps protect against meningitis caused by group C meningococcal meningitis and FSME-IMMUN/TicoVac is a vaccine that helps protect against tick-borne encephalitis. In connection with this acquisition, we recorded $376 million in Identifiable intangible assets, primarily consisting of $371 million in Developed technology rights. We also recorded $196 million of Inventories and $11 million in Goodwill. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has not yet been completed.
B. Collaborative Arrangements
Collaboration with Eli Lilly & Company (Lilly)
In October 2013, we entered into a collaboration agreement with Lilly to jointly develop and globally commercialize Pfizer's tanezumab, which provides that Pfizer and Lilly will equally share product-development expenses as well as potential revenues and certain product-related costs. On March 23, 2015, Pfizer and Lilly announced that the companies are preparing to resume the Phase 3 clinical program for tanezumab. As a result, we received a $200 million upfront payment from Lilly in accordance with the collaboration agreement between Pfizer and Lilly, which was recorded as deferred revenue in our condensed consolidated balance sheet as of March 29, 2015 and is being recognized into Other (income)/deductions net over a multi-year period beginning in the second quarter of 2015. This announcement followed a decision by the U.S. Food and Drug Administration (FDA) to lift the partial clinical hold on the tanezumab development program after a review of nonclinical data characterizing the sympathetic nervous system response to tanezumab. Under the collaboration agreement with Lilly, we are eligible to receive certain payments from Lilly upon the achievement of specified regulatory and commercial milestones, including the aforementioned upfront payment of $200 million, which was contingent upon the parties continuing in the collaboration after receipt of the FDA s response to the submission of the nonclinical data.
Collaboration with OPKO Health, Inc. (OPKO)
On December 13, 2014, we entered into a collaborative agreement with OPKO to develop and commercialize OPKO s long-acting human growth hormone (hGH-CTP) for the treatment of growth hormone deficiency (GHD) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (SGA) who fail to show catch-up growth by two years of age. hGH-CTP has the potential to reduce the required dosing frequency of human growth hormone to a single weekly injection from the current standard of one injection per day. The transaction closed on January 28, 2015, upon termination of the waiting period under the Hart-Scott Rodino Act. In February 2015, we made an upfront payment of $295 million to OPKO, which was recorded in Research and development expenses, and OPKO is eligible to receive up to an additional $275 million upon the achievement of certain regulatory milestones. We have received the exclusive license to commercialize hGH-CTP worldwide. Subject to regulatory approval, OPKO is eligible to receive royalty payments associated with the commercialization of hGH-CTP for Adult GHD. Upon the launch of hGH-CTP for Pediatric GHD, the royalties will transition to tiered gross profit sharing for both hGH-CTP and our product, Genotropin. OPKO will lead the clinical activities and will be responsible for funding the development programs for the key indications, which includes Adult and Pediatric GHD and Pediatric SGA. We will be responsible for all development costs for additional indications, as well as all postmarketing studies and the commercialization activities for all indications, and lead the manufacturing activities covered by the global development plan.
C. Equity-Method Investment
Investment in ViiV Healthcare Limited (ViiV)
Our minority ownership interest in ViiV, a company formed in 2009 by Pfizer and GlaxoSmithKline plc (GSK) to focus solely on research, development and commercialization of human immunodeficiency virus (HIV) medicines, was impacted by the January 21, 2014 European Commission approval of Tivicay (dolutegravir), a product for the treatment of HIV-1 infection, developed by ViiV. This approval triggered a reduction in our equity interest in ViiV from 12.6% to 11.7%, effective April 1, 2014. As a result, in the first quarter of 2014, we recognized a loss of approximately $36 million in Other (income)/deductions net.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example:
In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and
In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.
All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and research and development (R&D), as well as groups such as information technology, shared services and corporate operations.
In early 2014, we announced that we would be incurring costs in 2014-2016 related to new programs: our new global commercial structure reorganization and additional cost-reduction/productivity initiatives.
We have the following initiatives underway:
Manufacturing plant network rationalization and optimization, where execution timelines are necessarily long. Our plant network strategy is expected to result in the exit of six sites over the next several years. In connection with these activities, during 2014-2016, we expect to incur costs of approximately $300 million associated with prior acquisition activity and costs of approximately $1.5 billion associated with new non-acquisition-related cost-reduction initiatives. Through March 29, 2015, we incurred approximately $205 million and $293 million, respectively, associated with these initiatives.
New global commercial structure reorganization, which primarily includes the streamlining of certain functions, the realignment of regional locations and colleagues to support the businesses, as well as implementing the necessary system changes to support future reporting requirements. In connection with this reorganization, during 2014-2016, we expect to incur costs of approximately $300 million. Through March 29, 2015, we incurred approximately $179 million associated with this reorganization.
Other new cost-reduction/productivity initiatives, primarily related to commercial property rationalization and consolidation. In connection with these cost-reduction activities, during 2014-2016, we expect to incur costs of approximately $850 million. Through March 29, 2015, we incurred approximately $231 million associated with these initiatives.
The costs expected to be incurred during 2014-2016, of approximately $2.9 billion in total, include restructuring charges, integration costs, implementation costs and additional depreciation asset restructuring. Of this amount, we expect that about a quarter of the charges will be non-cash.
Current-Period Key Activities
In the first quarter of 2015, we incurred approximately $121 million in cost-reduction and acquisition-related costs (excluding transaction costs) in connection with the aforementioned programs, primarily associated with our manufacturing and sales operations.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:
Three Months Ended
(MILLIONS OF DOLLARS)
March 29,
2015
March 30,
2014
Restructuring charges(a):
Employee terminations
31
30
Asset impairments
Exit costs
Total restructuring charges
42
40
Transaction costs(b)
Integration costs(c)
13
18
Restructuring charges and certain acquisition-related costs
60
58
Additional depreciation asset restructuring recorded in our condensed consolidated statements of income as follows(d):
Cost of sales
17
74
Research and development expenses
Total additional depreciation asset restructuring
18
74
Implementation costs recorded in our condensed consolidated statements of income as follows(e):
Cost of sales
13
Selling, informational and administrative expenses
26
15
Research and development expenses
11
Total implementation costs
48
32
Total costs associated with acquisitions and cost-reduction/productivity initiatives
127
164
(a)
In the three months ended March 29, 2015, Employee terminations represent the expected reduction of the workforce by approximately 200 employees, mainly in manufacturing and sales.
The restructuring charges for the three months ended March 29, 2015 are associated with the following:
the Global Innovative Pharmaceutical segment (GIP) ($12 million); the Global Vaccines, Oncology and Consumer Healthcare segment (VOC) ($13 million); the Global Established Pharmaceutical segment (GEP) ($10 million); Worldwide Research and Development and Medical ($12 million); manufacturing operations ($22 million income); and Corporate ($18 million).
The restructuring charges for the three months ended March 30, 2014 are associated with the following:
the Global Innovative Pharmaceutical segment (GIP) ($2 million); the Global Established Pharmaceutical segment (GEP) ($7 million); Worldwide Research and Development and Medical ($1 million); manufacturing operations ($26 million); and Corporate ($4 million).
(b)
Transaction costs represent external costs directly related to acquired businesses and primarily include expenditures for banking, legal, accounting and other similar services.
(c)
Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes.
(d)
Additional depreciation asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
(e)
Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
The following table provides the components of and changes in our restructuring accruals:
(MILLIONS OF DOLLARS)
Employee
Termination
Costs
Asset
Impairment
Charges
Exit Costs
Accrual
Balance, December 31, 2014(a)
1,114
52
1,166
Provision
31
42
Utilization and other(b)
(127
(6
(30
(162
Balance, March 29, 2015(c)
1,019
28
1,046
(a)
Included in Other current liabilities ($735 million) and Other noncurrent liabilities ($431 million).
(b)
Includes adjustments for foreign currency translation.
(c)
Included in Other current liabilities ($648 million) and Other noncurrent liabilities ($398 million).
10
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 4. Other (Income)/Deductions Net
The following table provides components of Other (income)/deductions net:
Three Months Ended
(MILLIONS OF DOLLARS)
March 29,
2015
March 30,
2014
Interest income
(93
(92
Interest expense(a)
309
321
Net interest expense
216
229
Royalty-related income(b)
(222
(248
Certain legal matters, net(c)
694
Net gains on asset disposals(d)
(175
(181
Certain asset impairments(e)
115
Business and legal entity alignment costs(f)
101
29
Other, net
34
(15
Other (income)/deductions net
(46
623
(a)
Interest expense decreased in the first quarter of 2015, primarily due to lower interest rates on new fixed rate debt added in the second quarter of 2014 and the benefit of the effective conversion of some fixed-rate liabilities to floating-rate liabilities.
(b)
Royalty-related income decreased in the first quarter of 2015, primarily due to a decrease in royalties earned on Amgen Inc.'s sales of Enbrel in the U.S. and Canada due to a decrease in the royalty rate per the terms of the collaboration agreement.
(c)
In the first quarter of 2014, primarily includes approximately $620 million for Neurontin-related matters (including off-label promotion actions and antitrust actions) and approximately $50 million for an Effexor-related matter.
(d)
In the first quarter of 2015, primarily includes gains on sales/out-licensing of product and compound rights (approximately $45 million) and gains on sales of investments in equity securities (approximately $120 million). In the first quarter of 2014, primarily includes gains on sales/out-licensing of product and compound rights (approximately $70 million) and gains on sales of investments in equity securities (approximately $95 million).
(e)
In the first quarter of 2014, includes an intangible asset impairment charge of $114 million, virtually all of which relates to an in-process research and development (IPR&D) compound for the treatment of skin fibrosis. The intangible asset impairment charge for the first quarter of 2014 is associated with Worldwide Research and Development and reflects, among other things, the impact of changes to the development program.
(f)
In the first quarter of 2015 and 2014, represents expenses for planning and implementing changes to our infrastructure to align our operations and reporting for our business segments established in 2014.
Note 5. Tax Matters
A. Taxes on Income from Continuing Operations
Our effective tax rate for continuing operations was 22.9% for the first quarter of 2015, compared to 20.4% for the first quarter of 2014.
The higher effective tax rate for the first quarter of 2015 in comparison with the same period in 2014 was primarily due to:
a decline in favorable benefits associated with the resolution of certain tax positions pertaining to prior years, primarily with various foreign tax authorities, and the expiration of certain statutes of limitations,
partially offset by:
the favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business.
11
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
B. Tax Contingencies
We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution.
The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS:
With respect to Pfizer Inc., tax years 2009-2013 are currently under audit. Tax years 2014 and 2015 are open, but not under audit. All other tax years are closed.
In addition to the open audit years in the U.S., we have open audit years in other major tax jurisdictions, such as Canada (2004-2015), Japan (2013-2015), Europe (2007-2015, primarily reflecting Ireland, the United Kingdom, France, Italy, Spain and Germany), Latin America (1998-2015, primarily reflecting Brazil) and Puerto Rico (2009-2015).
C. Tax Provision/(Benefit) on Other Comprehensive Loss
The following table provides the components of the Tax provision/(benefit) on Other comprehensive loss:
Three Months Ended
(MILLIONS OF DOLLARS)
March 29,
2015
March 30,
2014
Foreign currency translation adjustments(a)
85
(7
Unrealized holding losses on derivative financial instruments, net
(224
(17
Reclassification adjustments for realized losses
183
(1
(41
(18
Unrealized holding gains/(losses) on available-for-sale securities, net
(31
27
Reclassification adjustments for realized (gains)/losses
(1
(29
(32
(2
Benefit plans: actuarial gains, net
12
Reclassification adjustments related to amortization
46
16
Reclassification adjustments related to settlements, net
15
Other
37
(12
109
13
Reclassification adjustments related to amortization
(13
(7
Reclassification adjustments related to curtailments, net
(4
(1
Other
(17
(3
Tax provision/(benefit) on other comprehensive loss
105
(17
(a)
Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.
12
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests
The following table provides the changes, net of tax, in Accumulated other comprehensive loss:
Net Unrealized Gains/(Losses)
Benefit Plans
(MILLIONS OF DOLLARS)
Foreign Currency Translation Adjustments
Derivative Financial Instruments
Available-For-Sale Securities
Actuarial Gains/(Losses)
Prior Service (Costs)/Credits and Other
Accumulated Other Comprehensive Loss
Balance, December 31, 2014
(2,689
517
(222
(5,654
733
(7,316
Other comprehensive income/(loss)(a)
(1,378
(41
(49
256
(29
(1,241
Balance, March 29, 2015
(4,067
476
(271
(5,398
703
(8,557
(a)
Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $16 million loss for the first three months of 2015.
As of March 29, 2015, with respect to derivative financial instruments, the amount of unrealized pre-tax gains estimated to be reclassified into income within the next 12 months is $435 million (which is expected to be offset primarily by losses resulting from reclassification adjustments related to available-for-sale securities).